REGN — Regeneron Pharmaceuticals, Inc.
$805.02-1.72%
Last close: · regular session
Last 60 sessions
REGN closed at $805.02 (-1.72%) on Oct 23, 2026. Float: 98.5M shares. Latest SEC filing: 8-K on Oct 6, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for REGN in the TickerWise workspace.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 15,158
- Website: https://www.regeneron.com
Latest SEC filings for REGN
Latest REGN news
- Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness Read article
- Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Read article
- Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share Read article
- Regeneron a new Buy at UBS as Street undervalues Dupixent's future Read article
- Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? Read article
- Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth Read article
- Why Regeneron (REGN) is a Top Value Stock for the Long-Term Read article
- Regeneron sees nearly $0.18 per share earnings headwind after Sanofi deal Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.